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SUMMARY
Treatment of status epilepticus (SE) in infants and children is challenging. There is a
recognition that a broad set of developmental processes need to be considered to fully
appreciate the physiologic complexity of severe seizures, and seizure outcomes, in
infants and children. The development and use of basic models to elucidate important
mechanisms will help further our understanding of these processes. Here we review
some of the key experimental models and consider several areas relevant to treat-
ment that could lead to productive translational research. Terminating seizures
quickly is essential. Understanding pharmacoresistance of SE as it relates to receptor
trafficking will be critical to seizure termination. Once a severe seizure is terminated,
how will the developing brain respond? Basic studies suggest that there are important
acute and long-term histopathologic, and pathophysiologic, consequences that, if left
unaddressed, will produce long-lasting deficits on the form and function of the central
nervous system. To fully utilize the evidence that basic models produce, age- and
development- andmodel-specific frameworks have to be considered carefully. Studies
have demonstrated that severe seizures can cause perturbations to developmental
processes during critical periods of development that lead to life-long deficits. Unfortu-
nately, some of the drugs that are commonly used to treat seizures may also produce
negative outcomes by enhancing Cl--mediated depolarization, or by accelerating pro-
grammed cell death. More research is needed to understand these phenomena and
their relevance to the human condition, and to develop rational drugs that protect the
developing brain from severe seizures to the fullest extent possible.
KEYWORDS: Status epilepticus, Neonatal seizures, Antiepileptic drugs, Brain devel-
opment, Epilepsy.
Experimental models of status epilepticus (SE) in the
young have provided important information regarding the
short- and long-term consequences of severe seizures. Most
of them are adapted from adult models of SE,1 and
comparisons of the young to the adult are complicated by a
host of developmental factors2 including, but not limited to,
differences in metabolic rate,3,4 shifting developmental
gene expression patterns,5 sequential receptor roles over
developmental time,6 and unsynchronized periods of neuro-
genesis, synapse formation, and synapse elimination,7 lead-
ing to selective windows of normal and pathologic8
programmed cell death in distinct cell populations.9 Given
that modeling human development in animals is fraught
with uncertainties,10 translational conclusions require con-
siderable caution but can reveal some basic principles.11
Recent clinical and basic studies have highlighted the
negative impact of SE in the young on brain and behavior,
including epileptogenesis,12,13 long-term changes in brain
imaging,14 as well as cognitive function.15,16 Although
some controversies remain, basic and clinical studies have
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converged.7,17–20 Basic studies have shown that the mecha-
nisms of seizure induction, and maintenance, can change
both over developmental time and during individual sei-
zures. Clinical studies have confirmed the adverse effects of
seizure activity on brain development and outlined the great
diversity of syndromes with unique clinical presentation of
SE, often linked to specific genetic defects.21–23
In an ideal scenario, basic models of developmental
SE would have clear translational value in a manner that
would inform acute treatments and the long-term care of
patients. Imitative models try to mimic the human illness
as closely as possible (the best model of a cat is another
cat, and preferably the same cat), whereas reductionist
models isolate one feature of the human illness to under-
stand its mechanism and design a treatment. Both types
can be useful for different purposes, and if they repro-
duce key clinical hallmarks predictably, efforts to under-
stand, and treat, the disease process can move forward.
Here we evaluate data derived from several models of
SE in the developing brain, with the hope that continued
research in this field will lead to more options and better
treatments in the clinic.
Pathophysiology of SE
Critical periods of brain development
There are many “critical periods” of brain development.
This concept can be traced experimentally back to Hans
Spemann at the turn of the twentieth century, and it was
related directly to synaptic activity and connectivity, by the
work of Hubel and Wiesel.24 Cell and synapse survival are
dependent on synaptic activity in a region- and developmen-
tal time-specific manner. Cortical visual networks that are
disconnected from visual input during a critical period do
not develop normally, and cannot regain full function, if
reconnected after the end of that period. Competition for
neurotrophins that are released in an activity-dependent
manner (some of which are known to be modified by
seizures25), during periods of synaptogenesis and synapse
stabilization, seems to be crucial to that process.
These principles also apply to disease processes, as illus-
trated by the effects of thyroid hormone on development:
thyroid hormone is required between prenatal day 3 and
postnatal day 5–10 (P5-10) for development of the audi-
tory system, and between birth and P20 for cerebellar
development. Restoration of thyroid function after P10 no
longer cures deafness, and thyroid hormone replacement
after P21 fails to restore cerebellar function, Purkinje cell
branching, or granule cell migration, showing that once a
critical period of central nervous system development is
bypassed, it cannot be retraced.26 Such precise timing is
not available for the effects of seizures on brain develop-
ment, but experimental data suggest that critical periods
often coincide with periods of rapid developmental change
in the affected neuronal population. For example, repeated
seizures during P9-P18 in rat pups reduce myelin accumu-
lation permanently,27 and around P20 they permanently
modify the field and function of hippocampal place cells.28
The context in which seizures occur varies dramatically
with age. The brain of the neonate and infant has a very low
metabolic rate and few excitatory circuits, so that some forms
of damage take longer to develop.3 Maturation follows a pro-
gressive curve,29 peaking during childhood in a brain with
more synapses, richer excitatory networks with proportionally
more CA2+-permeable a-amino-3-hydroxy-5-methyl-4-isoxa-
zolepropionic acid (AMPA) receptors,30,31 and a higher meta-
bolic rate than the adult brain, and these changes are
associated with high neuronal vulnerability but significant
potential for recovery. Adult and elderly brains display a
slightly lower metabolic rate, high vulnerability, and a lower
adaptive and recovery potential. We have to distinguish the
infant from the child, since the brain environment dramati-
cally alters seizure patterns and their consequences..
Pharmacoresistance
We have very effective mechanisms to stop seizures, yet
they sometimes fail and lead to self-sustaining, pharmacore-
sistant SE. Early pioneers like Trousseau understood that this
implies a change in the properties of the brain.
Seizure-induced increases in extracellular potassium32 and in
intracellular chloride33 facilitate depolarization and reduce
hyperpolarization, and depletion of key peptides34,35 tilts the
balance toward excitation. Inhibitory modulators, such as ade-
nosine, may become depleted extracellularly during extended
seizures.36,37 The most critical change in the transition from
single seizures to SE in adults may be the internalization and
temporary inactivation of synaptic c-aminobutyric acid A
(GABA)A receptors (GABAARs) in hippocampus and other
brain regions,38,39 which accounts, in part, for the failure of
GABAergic inhibition40 and for the poor response of estab-
lished SE to benzodiazepines and other GABAergic drugs.41
Seizure-induced receptor trafficking also increases synaptic
N-methyl-D-aspartate (NMDA) and AMPA receptors,42,43
Key Points
• At all ages tested (from postnatal day 7 to adulthood in
the rat), some long-lasting seizures cause neuronal
injury and leave chronic sequelae
• Even in the absence of neuronal death, status epilepti-
cus can adversely affect brain development
• The drugs used to treat seizures can also have deleteri-
ous effects on the developing brain, particularly in
neonates and infants
• More research is needed to understand the mecha-
nisms and improve treatment of early life seizures,
and to identify drugs that do not interfere with brain
development
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enhances excitatory drive, and may play an important role in
the maintenance phase of SE. These changes suggest that the
standard treatment consisting of benzodiazepinemonotherapy
followed by other antiepileptic drugs, then anesthesia,44
addresses only the GABAAR changes and leaves changes in
glutamate receptors untreated. Indeed, in experimental mod-
els of adult SE, combinations of GABAAR agonists with glu-
tamate receptor antagonists are synergistic45,46 and are far
more effective than benzodiazepines, especially when treat-
ment is late.47
There are few studies to tell us if these mechanisms apply
to the immature brain. In postnatal day 28 (P28) rats, self-sus-
taining SE and pharmacoresistance are present,48 but at P14,
perforant path stimulation delivered for 16 h consecutively
failed to make seizures self-sustaining,49 and pharmacoresis-
tance to diazepam was not seen in P14 rat pups in lithium-
pilocarpine seizures48 or in P21 rats in soman-induced sei-
zures.50 Treatment with glutamate receptor antagonists has
been successful in some models51 but has not been investi-
gated systematically in immature animals. NMDAR antago-
nists display age-specific toxicity, which precludes their use
in the very young.52 Given that GABAARs are underrepre-
sented, and glutamate receptors are overrepresented, in the
immature brain (postinfancy), we need to understandwhether
similar transitions occur during SE in the highly connected
young brain, and in the very young, which do not typically
display seizure generalization and self-sustaining SE.49
Seizure circuits
In adult, free-running animals, SE tends to become self-
sustaining (SSSE) and to continue for hours after the icto-
genic stimulus is withdrawn. This is true of seizures
induced by chemical48,53,54 as well as electrical stimula-
tion.55,56 Robust electrographic activity that remains con-
fined to a pathway in the young,49 would typically spread
and generalize in the adult.57 This may lead to the different
behavioral seizure phenotypes, with a paucity of
convulsive activity commonly reported in very young ani-
mals,58–60 and likely also results in regional or focal vul-
nerabilities in the immature brain. This “electroclinical
dissociation” has been discussed in relation to treatment in
neonates.61 Global brain scans may, or may not, detect iso-
lated lesions,15 but the reports of long-term sequelae7,17,62
suggest that neuronal death and related pathologic changes
can result directly from SE in the young. Understanding
the conditions that are critical for the transition from stimu-
lus-bound seizures to SSSE may help us to understand at
what point SE becomes intractable and brain damaging,
and how to prevent these consequences.
SE and neuronal injury/death
Does SE damage the immature brain?
Autopsies show widespread neuronal death in children
dying from prolonged febrile convulsions or SE but cannot
tell us whether seizures caused neuronal injury. Key studies
reported associations between mesial temporal sclerosis and
early SE or extended febrile convulsions.63–65 These find-
ings supported the pursuit of animal models that could
explain the human data in the immature brain. Adult animal
models of SE using seizure induction with kainate,66 high-
dose pilocarpine,67 lithium-pilocarpine,68 or electrical stim-
ulation,69 produce neuronal injury, including hippocampal
sclerosis and secondary epileptogenesis. Several models
have been adapted for use in immature animals.49,58,70–73
Studies in young animals using convulsants that reliably
produced SE and seizure-induced damage in adult rats,
reported differences from mature animals in seizure-induc-
tion thresholds, mortality, electrographic and behavioral
seizure phenotype, and in histopathologic outcomes. It is
clear that the impact of SE in young animals has to be evalu-
ated in a model-specific framework.
Chemoconvulsant models of SE in the first weeks of life
Kainic acid (KA), when delivered at doses comparable to
those in adult animals has a mortality rate as high as 90% in
15-day-old rats. This complication can lead to 2 obvious
problems. One problem is the selection bias of surviving
animals that experience less severe seizures, and another
problem is that by adjusting doses downward to improve
survival, less severe seizures are produced. When KA sei-
zures are experienced by rats 2 weeks of age, the animals
progress through electroencephalography (EEG) and behav-
ioral seizure stages phenotypically different from
adults.58,74,75 These differences make direct comparisons to
adult animals tenuous. The fact that immature rabbits expe-
rience hippocampal damage following KA-induced seizures
suggests that model-specific effects need to be consid-
ered.76
Pilocarpine given at a high dose reliably produces SE and
widespread damage, including severe hippocampal sclero-
sis, in the adult brain.67When moderate and high doses were
given to rats in the first weeks of life, complex behavioral
alterations did not manifest reliably within the first week,
and only some of the animals showed signs recognized as
limbic seizures at P12.59 The seizures became more robust
and consistent with the adult pattern of EEG and behavior
by the third week of life, but lethality also increased. Dam-
age was seen in some of these animals, but fewer than would
be anticipated by the adult model.
On first analysis, the studies looking for histopathologic
effects and sequelae of SE in the immature brain seemed to
show a resistance to damage.58,59 These basic data have
been used to argue that the immature brain is selectively
resistant to seizure-induced death,10,77 and that clinicians
might better serve their patients by stopping convulsive
activity and focusing on the underlying cause of the SE
rather than the seizures per se.78 This concept that severe
extended seizures in the young were benign was challenged
by a number of studies using different models of SE.
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Lithium pretreatment allows lower doses of pilocarpine
to induce SE. The reduction of peripheral side effects at
lower dose reduces mortality. This model produces robust
SE in P12-P15, and reliably shows widespread damage that
predominates in the hippocampus72 (Fig. 1 A–B), and in
extratemporal lobe areas.70,79 It also produces secondary
epileptogenesis with spontaneous recurrent seizures.72 His-
tologic evidence of damage in immature animals has been
confirmed by elevated serum levels of neuron-specific eno-
lase, a marker of neuronal death.80 In addition, immature
rabbits show hippocampal and extrahippocampal lesions
resulting from lithium-pilocarpine seizures73 showing that
seizure-induced damage can be demonstrated in multiple
models (Fig. 1D).
It is important to note that recent studies using P7-P10 rat
pups, which are developmentally similar to human neo-
nates, and which also have been assumed to be refractory to
seizure-induced neuronal injury, display neuronal death in
the absence of hypoxemia and long-term sequelae following
SE. P10 rat pups show acute and chronic damage and
epileptogenesis following 30 min of SE.81 P7 animals show
widespread acute neuronal death in a model of severe SE82
(Fig. 1C).
SE induced by electrical stimulation
A model of perforant path stimulation (PPS) in 2-week-
old rats was adapted from an adult model in anesthetized
rats.83 In the P14-P16 rats, the long-lasting anesthetic
urethane could not be used because it caused enhanced dam-
age in areas undergoing programmed cell death within the
piriform cortex.84 The pups were fitted with chronic head
implants, and the perforant path was stimulated unilaterally
in free-moving animals. This seizure-like stimulation
induced selective loss of GABAergic hippocampal
interneurons, as well as principal cells, in the stimulated hip-
pocampus, and left the contralateral hippocampus intact,
demonstrating that neuronal death was the result of seizure
activity and not due to hypoxia or other systemic factors.
There was an early phase of apoptotic death in the border
between the hilus and dentate granule cells (Fig. 1E), fol-
lowed by losses in the hilus proper and principal cells. Of
interest, even with continuous long-term stimulation, the
animals did not enter SSSE as older animals subjected to the
same conditions typically do.56 This demonstrated that even
in the developing brain, sustained focal seizure-like
discharge can damage an overactive neural network.
Hyperthermia-induced seizures
Hyperthermia-induced seizures, used to model febrile
seizures, show clear long-term impacts such as enhanced
hippocampal excitability, and the occurrence of sponta-
neous seizures in some animals.85 Hippocampal and
extrahippocampal injury has been reported in this model
using silver staining, but no gross detectable cell drop out
could be detected chronically, although unbiased stereology
was not used. A study using magnetic resonance imaging
(MRI) did show hippocampal abnormalities and associated
learning and memory deficits in some animals.15 A signifi-
cant portion of pups with long-lasting seizures displayed
increased hippocampal T2 signal acutely, and atrophy,
chronically, on MRI. MRI studies performed in children
with prolonged febrile seizures86 show acutely increased
hippocampal T2 evolving into hippocampal atrophy in a siz-
able subset of patients. It is notable that experimental stud-
ies suggest that hyperthermia may be a major contributor to
seizure-associated neuronal injury in the young81 (Fig. 2).
Adverse effects of seizures in the reported absence of
neuronal death
Not all basic studies investigating the histopathologic
consequences of recurrent seizures or SE in the young have
reported observable, or permanent, cell damage in limbic
structures that is typically detected using conventional
methods in mature animals,712,7,87 although ruling out a
small amount of cell death is difficult.88 Recovery may be a
major factor in some neuronal populations. Cell injury, or
loss, may be compensated for by ongoing neurogenesis (de-
velopmental and/or seizure-induced).89 Synapse prolifera-
tion and survival during critical periods of development are
dependent on trophic support, and seizure-induced upregu-
lation of trophic factors such as brain-derived neurotrophic
factor25 may also compensate by preventing signs of atro-
phy. However, seizures can adversely affect brain develop-
ment even in the absence of neuronal death and atrophy, and
they do so in a strikingly age-specific fashion.
Repeated, single, flurothyl-induced seizures,60,90 or a sin-
gle bout of SE4 induced in infant rats, can inhibit DNA and
protein synthesis, irreversibly reduce brain weight, delay
behavioral milestones,91 and reduce seizure thresholds, in
the absence of histologic cell loss.92 Seizures occurring after
the peak of brain mitotic activity do not reduce brain cell
number, but curtail the build-up in myelin27 and in synaptic
markers,93 suggesting a reduction in dendritic and/or axonal
growth. Seizures throughout brain development inhibit pro-
tein synthesis in the regions of the brain most actively
involved in seizure activity.94 Recurrent flurothyl seizures,
delivered over the course of several days, produce aberrant
mossy fiber sprouting, a long-lasting reduction in seizure
thresholds, and spatial memory deficits.16,92,95 Alteration of
developmental regulation of synaptic circuits in the
hippocampus by early life seizures has been implicated in
long-term cognitive deficits.7
Many investigators have considered the deleterious
effects of developmental SE to be the result of transient
seizure-mediated perturbations in developmental
sequences.2,7 Genetic and developmental programming
dysregulation,5 disturbances in neurogenesis,89 circuit
building, and pruning96 are all believed to contribute to
many of the adverse outcomes that have been described
following SE. But so too would cell loss generated by
Epilepsia Open, **(*):1–11, 2018
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severe seizures.13,14,97,98 One possibility is that there is
not a strict dichotomy between pathophysiology with
damage and pathophysiology without damage, and that
the insults to the immature brain caused by SE lie on a
continuum of cell death and injury. Conceptual rejection
of this dichotomy has been posited in the clinical litera-
ture as well.99–101 Considering SE-induced neuronal dam-
age in the young on a continuum helps to reconcile
conflicting data in the literature.1,11,102 For example, using
an identical lithium-pilocarpine model and the same rat
strain, one group of researchers reported chronic hip-
pocampal neuronal loss in only a limited subset of ani-
mals that experienced hours of SE and went on to develop
spontaneous seizures,103 whereas another group using sen-
sitive staining techniques that detect acute neuronal injury
found damage in 100% of animals.79
Seizures, drugs, and neuronal injury
In addition to its vulnerability to seizures, the immature
brain is also vulnerable to some of the drugs used to treat
them.104 Both NMDA blockers and GABA agonists have
been shown to induce apoptosis during critical periods of
development, with different neuronal populations showing
vulnerabilities at different times in development.8,84,104 The
vulnerable period varies with the drug, but in rodents covers
mostly neonates and infants. This exacerbation of damage
may not be limited to GABAA agonists like benzodi-
azepines105,106 or barbiturates107 and NMDA blockers but
may extend to many commonly used anticonvulsants. These
drugs can cause damage at high dose, and recent data sug-
gest that at lower dose, some of them may have the capacity
to worsen seizure-induced damage and sequelae106 (Fig. 3).
Anesthetics may similarly cause neuronal apoptosis at
Figure 1.
Evidence of SE-associated cell death in the immature brain from several models. A1–4, Age-dependent variation in dentate granule cells
and hilar interneurons damaged after lithium-pilocarpine seizures in rats pretreated with lithium (A1). Limited eosin fluorescence is seen
in a 2-week-old pup 24 h after SE (A.2). A 3-week-old pup shows extensive damage to the hilar and outer granule cells (A.3). Damaged
hilar cells are also visible in a 4-week-old and an adult rat (A.4).B.1–4, CA1 of a 2-week-old (B.1), 3-week-old (B.2), and 4-week old pup
(B.3) shows a large number of eosinophilic cells (hematoxylin and eosin), whereas the CA1 of a mature rat (B.4) has fewer injured neu-
rons. Scale bars for A and B, 100 lm (figures taken from reference #63). C.1–2, Severe SE results in neuronal injury in both dorsal and
ventral CA1. Images of Fluoro-Jade B in CA1 show eosinophilia 24 h after seizure (SE24Hrs). C.2 is a higher magnification of the boxed
area on the image on the left. (figure taken from Reference #73).D, Histologic lesions in normoxemic rabbits after lithium-pilocarpine SE.
Lesions in CA1 were seen in all animals that had severe seizures. The most severe case of hippocampal damage is shown with total
destruction of the CA1 and CA3 pyramidal cell layers. E, In situ end-labeling 2 h after perforant path stimulation in the immature rat.
Labeled nuclei were seen in cells located within the inner layer of the granule cells bilaterally and cells within the hippocampus that con-
tained labeled nuclei were eosinophilic.
Epilepsia Open ILAE
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specific periods of early brain development.108 There are no
solid clinical data to tell us whether this vulnerability
applies to humans, although some clinical data seem to sup-
port the potential negative effects of early treatment with
specific antiepileptic drugs (AEDs).109,110
This “developmental drug-induced apoptosis” is a major
unresolved issue, since many of the drugs that cause it are
used clinically, for example, in the treatment of neonatal
seizures, where the drugs of choice are GABAergic, these
could depolarize neurons and remove the magnesium block
of NMDARs, and could cause, or aggravate, neuronal
injury. Drug-induced apoptosis could preferentially target
immature cells, so that the behavioral expression of that
damage would not appear until much later in development.
Recent evidence suggests that the standard drugs
recommended for treatment of neonatal seizures by the
International League Against Epilepsy (ILAE) aggravate
seizure-induced neuronal injury in P7 rats.106 Furthermore,
drugs that do not cause developmental drug-induced apop-
tosis104,111,112 are available but are not used as first-line
therapy. Further research into the mechanisms of this drug-
induced apoptosis, and its human relevance, if any, is
urgently needed.
Elevated glutamate release caused by excessive neuronal
discharge leads to unregulated Ca2+ entry into cells that can
cause long-term cellular dysregulation and excitotoxic brain
damage.113,114 The Ca2+ -permissive NMDA receptor has
been implicated in triggering both necrosis and apoptosis
during SE, and both NMDA and non-NMDA channels par-
ticipate in seizure-induced cell death.115,116 Blocking the
NMDA receptor with the open channel blocker MK-801
protects interneurons and principal cells from PPS-induced
damage and preserves GABA-mediated inhibition that
would otherwise be lost. Treatment with MK-801 protects
neurons without necessarily stopping seizure discharge,117
so NMDA blockade may be a reasonable neuroprotection
strategy in SE that is super-refractory118 in the adult, but
NMDA blockers can induce widespread neuronal loss in
neonates and infants.104,119 For that reason, NMDA block-
ers are not clinically usable in the very young.
Basic studies reveal intriguing developmental differences
between NMDA channel participation in the seizure circuits
of the young and mature hippocampus that are unrelated to
apoptosis. The NMDA open channel blocker MK-801,
administered during perforant path stimulation in P15-P16
free-moving rats, produced an immediate loss of frequency-
dependent paired-pulse inhibition (in the absence of brain
damage).120 This drug-induced effect is not seen in the adult
model. In fact, NMDA blockade can restore paired-pulse
inhibition in the damaged adult brain following PPS.121This
striking difference between the immature and mature sys-
tem suggests that there are unique glutamatergic receptor
profiles6 and/or circuits that modulate hippocampal inhibi-
tion in the young brain that are lost, or reorganized, later in
development. These data also suggest that pharmacologic
manipulation of inhibitory circuits may be a route to control
highly excitable immature hippocampal circuits.
It is interesting that NMDA blockade can protect from
seizure-induced apoptotic cell death in some areas of the
immature brain, while at the same time causing an enhance-
ment of apoptosis in other regions. NMDA blockade pro-
duces partial protection of both hilar interneurons
(presumably both inhibitory interneurons and excitatory
“mossy cells”) during PPS. Subtypes of GABAergic neu-
rons containing peptide transmitters are lost in both the
immature and adult brain following PPS, in a pattern similar
to that found in resected tissue from humans with temporal
lobe epilepsy.122 The loss of paired-pulse inhibition at the
Figure 2.
Acute neuronal injury after 30 min of lithium-pilocarpine SE in P10
rat pups.A, At 24 h, both hyperthermia SE (HT + SE, temperature
during SE 39  10°C) animals and normothermia SE animals
(NT + SE, temperature during SE 35  10°C) showed Fluoro-
Jade B–positive neurons in CA1 and DG of hippocampus. B, The
severity of the neuronal injury was significantly higher in HT + SE
animals. Severity score is shown on the y-axis. Abbreviations: SO,
stratum oriens; , stratum radiatum; SLM, stratum lacunosum
moleculare; SP, stratum pyramidale; CA1, cornus ammonis region;
DG, dentate gyrus. Scale bar 100 lm. Values are means  SEM,
t-test, p < 0.05.
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outset of the experiments showed that that some GABAer-
gic neurons were taken “off line” during the seizure-like
stimulation, and this was likely protective for them. In addi-
tion to protecting GABAergic cells, NMDA blockade pro-
tected granule cells that would otherwise die within 24 h,
with the hallmarks of apoptosis, in untreated animals.
Conclusion
The immature brain can be harmed by severe seizures in a
model-, convulsant-, age-, and pathway-dependent manner.
Seizure-induced cell death in the immature brain can occur
as a result of intense neuronal firing in the absence of
Figure 3.
Effect of midazolam (Mz) or phenobarbital (Ph) treatment on status epilepticus (SE)–associated neuronal injury in caudate putamen and
thalamus, and mechanism of thalamic injury in P7 rat pups. SE was induced with high-dose lithium (5 mEq/kg, i.p.) and pilocarpine
(320 mg/kg, s.c.). Pups remained normoxemic during SE. Treatment was given after 10 min of SE. A, Fluoro-Jade B (FJB) staining in cau-
date putamen of (A1) SE, (A2) SE + Mz, and (A3) SE + Ph pups with a higher magnification of the boxed area on the bottom right of each
image. SE induces neuronal injury throughout caudate, and this injury is exacerbated following midazolam or phenobarbital treatment. B,
Images of FJB staining in thalamus of (B1) SE, (B2) SE + Mz, and (B3) SE + Ph pups. Both midazolam and phenobarbital treatment
increase FJB cell distribution throughout various thalamic nuclei. Scale bars: (A) long bars = 200 lm and short bars = 20 lm; (B) long
bars = 500 lm and short bars = 50 lm. (C) Images of overlay of active caspase-3 (Casp-3a) immunoreactivity (green) and
4,6-diamidino-2-phenylindole (DAPI; blue) staining in thalamus of SE + Mz pups. On the left, high magnification shows distribution of
caspase-3a–immunoreactive cells in ventromedial thalamus of an SE + Mz pup; in the middle, high-magnification images show that cas-
pase-3a–immunoreactive cells have fragmented nuclei indicative of neuronal cell death; on the right, this overlay shows that many of these
caspase-3a–immunoreactive cells have fragmented nuclei, suggesting a caspase-dependent form of cell death. Scale bars = 50 lm.
Epilepsia Open ILAE
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systemic changes49,72,73 and can have lasting effects on
behavior including learning and memory.7,72,87,95,123 Fur-
thermore, because most neurons are postmitotic, recovery is
limited, and seizure-induced damage experienced early in
life may have deleterious consequences that extend well
into maturity.
The damage produced by PPS stimulation in the imma-
ture free-moving rat demonstrates a reproducible pattern of
damage to both principal neurons and subclasses of inhibi-
tory neurons. The damage can resemble mesial temporal
lobe sclerosis.65 Hyperthermia-induced seizures produce
MRI abnormalities, and, in a pattern and evolution that is
reminiscent of human cases.12,13,124 The lithium-pilocar-
pine model, in 2- and 3-week-old rats produces hippocam-
pal damage (predominating in CA1 at P14) with mossy fiber
sprouting and extrahippocampal damage.72,79 Both the
hyperthermia-induced model, and the lithium-pilocarpine
model, can lead to the development of spontaneous recur-
rent seizures.72,87
The developmental models of SE reveal highly age- and
model-dependent processes in the immature brain that need
to be better understood through basic studies. Even in the
absence of cell death, SE can have adverse effects on brain
development. Pursuing new animal models will be impor-
tant to accurately reproduce the spectrum of severe seizures
experienced by children.1,21,125 As basic mechanisms of
SE-induced cell death, synaptic reorganization, and devel-
opmental disruption are revealed, translational research
seeking clinically useful neuroprotectants and/or antiepilep-
togenic drugs will likely progress.
We are beginning to understand the pathophysiology of
SE in the adult, but these mechanisms may be age-depen-
dent as well, and we still have little information on the onto-
geny of SE. Animal studies have revealed that receptor
trafficking during seizures can complicate treatments for
convulsions and electrographic seizures.47 Additional bio-
chemical and molecular studies designed to understand the
transition to self-sustaining seizures in developmental mod-
els of SE are needed. Determining whether receptor traffick-
ing is related to this transition, and eventual refractoriness
of seizures, will be clinically important. These types of stud-
ies would also be helpful to determine whether monother-
apy or polytherapy is best suited for SE in children.
Developing anticonvulsants that terminate seizures early
is important, but studies showing that commonly used anti-
convulsants can themselves produce neuronal loss compli-
cates the picture considerably.104,106 Enhancing inhibition,
and blocking excitation, during critical periods of synapto-
genesis can block trophic support that determines synapse
and cell survival. The pharmacologic challenge is made
even more complex due to the sliding time window of vul-
nerability across brain regions.8 Some clinical studies have
made indirect connections to AED therapies and induced
apoptosis.126 Many, but not all,111 AEDs can trigger neu-
ronal apoptosis in specific brain regions at specific ages,
especially in neonates and infants. Any clinical response to
SE in the young has to take into account the delicate balance
between the danger of seizures and the dangers of treatment.
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